Stereotaxis (NYSEAMERICAN:STXS) Shares Down 6.2% – Time to Sell?

Posted by Brian Himes on Oct 31st, 2026

Stereotaxis Inc. (NYSEAMERICAN:STXS – Get Free Report) traded down 6.2% on Thursday. The company traded as low as $0.91 and last traded at $0.91. 810,452 shares traded hands during trading, an increase of 41% from the average session volume of 574,679 shares. The stock had previously closed at $0.9703.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on STXS shares. Citigroup reiterated an “outperform” rating on shares of Stereotaxis in a report on Thursday, August 27th. TD Cowen cut their price target on Stereotaxis from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, August 12th. Finally, Citizens Jmp decreased their price objective on Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 27th. Five equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Stereotaxis currently has an average rating of “Buy” and a consensus target price of $3.50.

Check Out Our Latest Stock Report on Stereotaxis

Stereotaxis Price Performance

The company has a market capitalization of $86.43 million, a PE ratio of -3.59 and a beta of 1.37. The company’s fifty day moving average is $1.22 and its 200-day moving average is $1.72.

Stereotaxis (NYSEAMERICAN:STXS – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Stereotaxis had a negative return on equity of 130.84% and a negative net margin of 74.24%. The business had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $8.35 million. Equities research analysts forecast that Stereotaxis Inc. will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Stereotaxis

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in shares of Stereotaxis during the second quarter valued at about $364,000. Sequoia Financial Advisors LLC bought a new stake in shares of Stereotaxis in the 1st quarter valued at about $700,000. Sei Investments Co. grew its position in shares of Stereotaxis by 108.9% in the 1st quarter. Sei Investments Co. now owns 518,884 shares of the company’s stock worth $955,000 after buying an additional 270,443 shares during the last quarter. Finally, Integrity Alliance LLC. purchased a new position in shares of Stereotaxis in the 3rd quarter worth approximately $860,000. Institutional investors own 45.35% of the company’s stock.

About Stereotaxis

(Get Free Report)

Stereotaxis, Inc develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias.

The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart.